Vera Therapeutics, Inc.

VERA

$33.05

Updated: 24/09/2026, 01:01:44

Market Cap

$2.37B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for VERA

Company Profile

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

USD

NASDAQ

CEO: Marshall Fordyce

Employees: 361

https://veratx.com

Asset Summaries

Latest generated summaries for VERA

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for VERA.

Share price: $33.05
Market cap: $2.37B
Exchange: NASDAQ
Currency: USD
CEO: Marshall Fordyce
Employees: 361
IPO date: 14/05/2021
Beta: 0.953
Last dividend: $0.00
Day range: $32.63 – $36.27
52-week range: $23.05 – $56.05
1-day performance: -8.85%
1-year performance: 43.38%
Current drawdown (1Y): -41.03%
CIK: 0001831828
CUSIP: 92337R101
ISIN: US92337R1014
Created: 07/12/2025, 14:57:09
Last update: 24/09/2026, 01:01:44

Track Vera Therapeutics, Inc. with an AI analyst

See which prediction-market events move VERA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to VERA from your Railway `news_articles` table.

$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly

24/7 Wall Street • STOCK • 04/06/2026, 11:29:30

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

GlobeNewsWire • STOCK • 02/06/2026, 09:00:00

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

GlobeNewsWire • STOCK • 04/05/2026, 09:30:00

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

GlobeNewsWire • STOCK • 25/03/2026, 08:30:00

Vera Therapeutics, Inc. (VERA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • STOCK • 06/03/2026, 16:05:54

Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade)

Seeking Alpha • STOCK • 20/02/2026, 17:00:27